MORAGA, Calif. -- Liddell Laboratories announced today that the first shipment of its new antiviral medicine designed for SARS patients will arrive in China and Hong Kong this week for clinical testing.
This medicine, carrying the test-name Anti-Viral 2003, will be evaluated by doctors at the PLA General Hospital in Beijing, Shenzhen Renmin Hospital in Shenzhen and two independent medical clinics in Hong Kong.
In formulating Anti-Viral 2003, Liddell has been able to strengthen the immune-provoking effects of an existing Liddell antiviral medicine. Randy Powers, president of Liddell Laboratories, points out that the effectiveness of Anti-Viral 2003 against SARS will only be determined after detailed clinical testing on SARS patients.
Anti-Viral 2003 consists of several homeopathic ingredients specifically designed to provoke an increased immune response by the body in a manner similar to interferon (a naturally occurring protein which helps the body to counter infection). Ingredients are also present to stimulate T4 counts, ease respiratory inflammation and to lower fever. Because the medicine is safe -- no known negative side effects, drug interactions or contraindications -- it can also be used to complement other medications that may be discovered to treat severe viral infections like SARS or to treat SARS symptoms.
Powers says that in some ways, Anti-Viral 2003 may parallel one of homeopathy's first major successes. In the late 19th century, homeopathic medicines proved far more effective than conventional treatment against another viral infection -- Yellow Fever. With homeopathic treatments, doctors were able to reduce fatality rates from Yellow Fever by more than 50 percent.
"We must look at new and innovative ways to fight emerging diseases," says Powers. "The SARS outbreak was unprecedented in the speed with which it spread. I hope that we are able to contribute to the efforts of health authorities in learning more appropriate responses to emerging infections."
Source: Liddell Laboratories
COVID-19 Harmonization: Balancing Risks and Benefits of CDC's Latest Move
March 11th 2024The CDC's recent decision to align recommendations for respiratory viruses, particularly COVID-19, has garnered support from the public and infectious disease societies. However, as the Infectious Diseases Society of America (IDSA) lends its backing to the CDC's harmonization efforts, concerns persist regarding the implications of this shift, especially considering the Omicron variant's unique characteristics and the ongoing challenges posed by COVID-19's multi-system impacts.
Voices of Resilience: Q&A With the Editor of "Corona City: Voices From an Epicenter"
March 1st 2024Step into the diverse and poignant world of "Corona City: Voices From an Epicenter" with editor Lorraine Ash, MA. In this insightful Q&A, learn about the origins of this remarkable anthology, the challenges faced in capturing raw, unfiltered narratives of the COVID-19 pandemic, and the lasting impact of these stories on readers and communities alike.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.
COVID-19 Realities: Beyond a Respiratory Virus, Addressing Optimism in Pandemic Management
February 28th 2024A recent commentary by Dr. Amesh Adalja in MedPage Today challenges the perception of COVID-19 as solely a respiratory virus, highlighting its broader impact on the body. This analysis questions the notion that COVID-19 should be managed like common respiratory infections, urging a closer look at vaccine effectiveness, the rise of long COVID, and the need for enhanced measures to curb the virus's spread. Let's explore the complexities of COVID-19 management and the pressing realities faced by the US and the world.
COVID-19 Harmonization: Balancing Risks and Benefits of CDC's Latest Move
March 11th 2024The CDC's recent decision to align recommendations for respiratory viruses, particularly COVID-19, has garnered support from the public and infectious disease societies. However, as the Infectious Diseases Society of America (IDSA) lends its backing to the CDC's harmonization efforts, concerns persist regarding the implications of this shift, especially considering the Omicron variant's unique characteristics and the ongoing challenges posed by COVID-19's multi-system impacts.
Voices of Resilience: Q&A With the Editor of "Corona City: Voices From an Epicenter"
March 1st 2024Step into the diverse and poignant world of "Corona City: Voices From an Epicenter" with editor Lorraine Ash, MA. In this insightful Q&A, learn about the origins of this remarkable anthology, the challenges faced in capturing raw, unfiltered narratives of the COVID-19 pandemic, and the lasting impact of these stories on readers and communities alike.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.
COVID-19 Realities: Beyond a Respiratory Virus, Addressing Optimism in Pandemic Management
February 28th 2024A recent commentary by Dr. Amesh Adalja in MedPage Today challenges the perception of COVID-19 as solely a respiratory virus, highlighting its broader impact on the body. This analysis questions the notion that COVID-19 should be managed like common respiratory infections, urging a closer look at vaccine effectiveness, the rise of long COVID, and the need for enhanced measures to curb the virus's spread. Let's explore the complexities of COVID-19 management and the pressing realities faced by the US and the world.
2 Commerce Drive
Cranbury, NJ 08512